84 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment … with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known
8-K
EX-1.1
m6z8ovo3s80quew2kx
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
9h2k 2ckqq356osw
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
ef4ci6ujxifw14c6
29 Aug 23
Cost Associated with Exit or Disposal Activities
7:05am
8-K
EX-1.1
p3ig7ad
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
zqr3n72ocheswmcue
24 Mar 22
Prospectus supplement for primary offering
8:02pm